RASGRP4 as A Potential Drug Target and Biomarker for Diseases

Target Name: RASGRP4

NCBI ID: G115727

RASGRP4

RASGRP4 as A Potential Drug Target and Biomarker for Diseases

RASGRP4 (RAS-associated protein G) is a protein that is expressed in various tissues and cell types in the human body. It is a member of the RAS (Receptor-activated protein of G protein-coupled tyrosine kinases) family, which is a well-known signaling pathway that regulates various cellular processes in the body. RASGRP4 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-specific relevance

RASGRP4 is involved in various cellular processes that are crucial for the development and progression of various diseases. Its expression has been observed in various disease-related samples, including cancer, neurodegenerative diseases, and autoimmune disorders. It is also overexpressed in various diseases, which suggests that targeting RASGRP4 may be an effective strategy for treating these diseases.

RASGRP4 functions as a negative regulator of the RAS/MAPK signaling pathway, which is a well-known signaling pathway that regulates various cellular processes, including cell growth, differentiation, and survival. The RAS/MAPK pathway is activated by various signals, including growth factors, oxygen, and radiation, and it regulates the production of various signaling molecules, including pro-inflammatory cytokines and pro-apoptotic proteins.

RASGRP4 functions as a negative regulator of the RAS/MAPK pathway by preventing the activation of the MAPK signaling pathway. It does this by interacting with the MAPK-activating protein (MAPKAP) and by inhibiting the phosphorylation of several MAPKs, including ERK1/2, PRK1/2, and PRK2. This interaction between RASGRP4 and MAPKAP provides a negative feedback mechanism that keeps the RAS/MAPK pathway in a state of inactivity.

In neurodegenerative diseases, RASGRP4 has been implicated in the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These diseases are characterized by the progressive loss of neurons and the disruption of various signaling pathways, including the RAS/MAPK pathway.

In cancer, RASGRP4 has been observed to be overexpressed in various types of cancer, including breast cancer, lung cancer, and colorectal cancer. The overexpression of RASGRP4 in cancer cells may contribute to their aggressive behavior and the development of resistance to chemotherapy.

RASGRP4 as a biomarker

RASGRP4 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its expression has been observed in various disease-related samples, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, RASGRP4 has been used as a biomarker for various types of cancer, including breast cancer, lung cancer, and colorectal cancer. Studies have shown that RASGRP4 is overexpressed in cancer cells and that its expression is associated with the development and progression of these diseases.

In neurodegenerative diseases, RASGRP4 has been used as a biomarker for the diagnosis and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. The overexpression of RASGRP4 in neurodegenerative disease samples has been observed and its expression is associated with the severity and progression of these diseases.

In autoimmune disorders, RASGRP4 has been used as a biomarker for the diagnosis and progression of various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. The overexpression of RASGRP4 in autoimmune disease samples has been observed and its expression is associated with the severity and progression of these disorders.

Targeting RASGRP4

RASGRP4 is a protein that is still under

Protein Name: RAS Guanyl Releasing Protein 4

Functions: Functions as a cation- and diacylglycerol (DAG)-regulated nucleotide exchange factor activating Ras through the exchange of bound GDP for GTP. May function in mast cells differentiation

The "RASGRP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RASGRP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets